Morgan Stanley Alaunos Therapeutics, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.04 - $0.13 $9,790 - $31,818	244,755 New	244,755 $17,000
Q4 2023 Feb 13, 2024	SELL	$0.04 - $0.13 $3,308 - $10,752	-82,712 Reduced 25.26%	244,756 $17,000
Q3 2023 Nov 15, 2023	SELL	$0.12 - $0.5 $33,573 - $139,889	-279,778 Reduced 46.07%	327,468 $42,000
Q2 2023 Aug 14, 2023	SELL	$0.43 - $0.65 $24,189 - $36,565	-56,255 Reduced 8.48%	607,246 $309,000
Q1 2023 May 15, 2023	SELL	$0.46 - $0.81 $347,912 - $612,628	-756,332 Reduced 53.27%	663,501 $418,000
Q4 2022 Feb 14, 2023	BUY	$0.5 - $261.0 $336,911 - $176 Million	673,822 Added 90.32%	1,419,833 $922,000
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $136,271 - $42.3 Million	-131,030 Reduced 14.94%	746,011 $1.28 Million
Q2 2022 Oct 27, 2022	SELL	$0.41 - $1.24 $35,056 - $106,023	-85,503 Reduced 8.88%	877,041 $1.09 Million
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $35,056 - $106,023	-85,503 Reduced 8.88%	877,041 $1.09 Million
Q1 2022 Oct 27, 2022	BUY	$0.62 - $1.17 $53,011 - $100,038	85,503 Added 9.75%	962,544 $628,000
Q1 2022 May 13, 2022	BUY	$0.62 - $1.17 $39,216 - $74,006	63,253 Added 7.03%	962,544 $628,000
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $50,279 - $87,181	-46,128 Reduced 4.88%	899,291 $981,000
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $1.36 Million - $2.58 Million	945,419 New	945,419 $1.72 Million

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.